Home » Market News » DirectorsTalk Highlights » “SkinBioTherapeutics plc significant progress in the past six months” Dr. Cath O’Neill, CEO
SkinBiotherapeutics Plc

“SkinBioTherapeutics plc significant progress in the past six months” Dr. Cath O’Neill, CEO

SkinBioTherapeutics plc (LON:SBTX) a life sciences company focused on skin health, has announced its half year results for the six months to 31 December 2017.


— Significant progress in developing the SkinBiotix(R) technology; successful initial lysate manufacture scale-up

— Three different formulation options for the cosmetic application are being assessed ahead of the human study scheduled in Q3 2018

— Anti-infection and eczema programmes progressing – application frequency and safe dosing levels determined

— Early stage commercial discussions with significant industry players continuing with respect to the cosmetic application

   --     Cash as at period end at GBP3.6m (2016: GBP0.4m)

Dr. Cath O’Neill, CEO of SkinBioTherapeutics, said: “We have made significant progress in the past six months around our SkinBiotix(R) technology and we are on track with the advancement of all three indications in cosmetics, anti-infection and eczema.

Our primary focus has been on developing the cosmetic application. Manufacturing scale-up and formulation is progressing to plan. As laid out at IPO, we intend to carry out the human safety study later this year.

There is a growing awareness of our SkinBiotix(R) platform technology from the skin healthcare industry, based on the reputation of our team and our ‘science-led’ business approach. With continued work on our technology and the start of human studies in Q3, we are building further value for shareholders and a strong position from which to hold potential commercial discussions.”

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.